New drug combo tested for Tough-to-Treat leukemia

This study is testing a combination of intensive chemotherapy (called Hyper-CVAD) and a targeted drug called ponatinib for adults with a specific type of acute lymphoblastic leukemia (ALL) that involves a genetic change called Philadelphia chromosome or BCR-ABL. The main goal is to see how well this combination works to control the disease and keep it from coming back (event-free survival), while also closely monitoring side effects. The treatment involves several cycles of therapy followed by a longer maintenance period.